Immune Response Biopharma, Inc. (c) 2010-2019

 

Press Releases TM

Immune Response BioPharma, Inc. To Provide a Limited Supply of 3000 Doses of Each of HIV Vaccine Remune & MS Vaccine NeuroVax for Right to Try Use for HIV & MS Patients: IRBP Will Take Advance Orders to Meet Patient Demand on A First Come Basis at $3k per Injection, Once 3k Doses Reserved No More Vaccine Will be Provided as IRBP Lacks Capacity to Manufacture More, IRBP to Take Advance Orders on Compassionate Use Webpage Under Construction: News to Follow

June 10th 2018

Immune Response BioPharma, Inc. Applauds the Passage of the Right to Try Bill Signed into Law: IRBP will File a Large Intent to Treat Patient Population; Treatment IND Under the Current FDA Expanded Access Program

June 10th 2018

Immune Response BioPharma, Inc. Remune BLA for Adults Update Files FDA FDRR Formal Dispute Resolution Request for Arbitration of Approval for Remune, if Necessary IRBP  Warns the FDA that IRBP will Seek Relief in Federal District Court,  IRBP Confident Remune will be Approved the Easy Way or the Hard Way, IRBP to make Remune Available for Right to Try Use 

April 7th 2018

 

Immune Response BioPharma, Inc. Remune Pediatric BLA  Update Pending to be Filed Under Protest FDA PDFUA Date TBD TBA

April 7th 2018

 

Immune Response BioPharma, Inc. Applauds Passage of House Bill & Endorses Congressional Federal Right to Try Bill Legislation 

April 7th 2018

 

 

 

 

 

 

 

Immune Response BioPharma, Inc.TM Copyright (C) 2010-2019  All Rights Reserved     www.immuneresponse.net